Serum Metabolites and Kidney Outcomes: The Atherosclerosis Risk in Communities StudyPlain Language Summary

Authors :: Lauren Bernard
Linda Zhou
Aditya Surapaneni
Jingsha Chen
Casey M. Rebholz
Josef Coresh
Bing Yu
Eric Boerwinkle
Pascal Schlosser
Morgan E. Grams
Source :: Kidney Medicine, Vol 4, Iss 9, Pp 100522- (2022)
Publication Year :: 2022
Publisher :: Elsevier, 2022.
Abstract: Rationale & Objective: Novel metabolite biomarkers of kidney failure with replacement therapy (KFRT) may help identify people at high risk for adverse kidney outcomes and implicated pathways may aid in developing targeted therapeutics. Study Design: Prospective cohort. Setting & Participants: The cohort included 3,799 Atherosclerosis Risk in Communities study participants with serum samples available for measurement at visit 1 (1987-1989). Exposure: Baseline serum levels of 318 metabolites. Outcomes: Incident KFRT, kidney failure (KFRT, estimated glomerular filtration rate

Subjects :: 1-Linoleoylglycerophosphocholine
1,5-anhydroglucitrol
5-oxoproline
CKD progression
end-stage kidney disease
gamma-glutamylthreonine
Diseases of the genitourinary system. Urology
RC870-923

Full Text Access

Tools